Physician profile
William Love
NPI 1508069303
$4,094.94
in general payments reported to CMS, 2019-2025
23 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $23.09 · 2021: $48.47 · 2022: $45.13 · 2023: $493 · 2024: $1,797 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,837.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $694.23 | 2021-2025 | |
| Leo Pharma INC. | $595.96 | 2022-2025 | Adbry, Anzupgo |
| Convatec INC. | $496.97 | 2023-2025 | |
| Ucb, INC. | $401.17 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $372.01 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $276.60 | 2023-2025 | Ilumya, Odomzo |
| Janssen Biotech, INC. | $244.54 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $195.87 | 2019-2025 | Dupixent |
| Pfizer INC. | $182.45 | 2019-2025 | |
| Lilly USA, LLC | $144.93 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $97.05 | 2025 | |
| Arcutis Biotherapeutics, INC. | $83.46 | 2023-2025 | Zoryve |
| Incyte Corporation | $78.00 | 2021-2025 | Opzelura |
| Journey Medical Corporation | $48.34 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $36.20 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.88 | 2025 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.22 | 2024 | Spevigo |
| Organogenesis INC. | $19.78 | 2024 | Affinity |
| Merz North America, INC. | $18.12 | 2020 | |
| Biofrontera INC. | $17.59 | 2020-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $16.00 | 2025 | Sofdra |
| Allergan, INC. | $14.43 | 2021 | |
| Dusa Pharmaceuticals, INC. | $13.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.